Abstract 43P
Background
V-domain Ig suppressor of T-cell activation (VISTA) is a B7 family member that acts as an immune checkpoint regulator. VISTA is expressed in various cell subtypes such as tumor, myeloid, lymphoid, and endothelial cells. Within the tumor microenvironment (TME), its expression on myeloid cells favors immunosuppressive conditions and prevents T cell recruitment into tumors. In patients, high VISTA expression is associated with poor prognosis in multiple tumor indications, and act as a mediator of resistance to immune checkpoint therapies. Thus, VISTA appears as a potential therapeutic target in oncology requiring a more detailed characterization of its expression pattern across tumor indications to eventually inform future patient selection.
Methods
In tissue microarrays (TMAs) covering 23 solid tumor indications and representing more than 1000 patients, we investigated the expression of VISTA in combination with different immune and tumor cells markers. For this purpose, we developed and validated a 7-color multiplex immunofluorescence protocol to quantify VISTA expression on tumor cells (Cytokeratin/Melan A), cytotoxic CD8 T cells (CD8), myeloid cells (CD33), M2 macrophages (CD163), and PD-L1 positive cells (PD-L1).
Results
Consistent with the literature, we have observed that VISTA is not only predominantly expressed in the TME but also frequently and highly expressed in tumor cells in some indications such as sarcoma, mesothelioma, kidney, and gastric cancer for example. In the TME, VISTA is found to be highly expressed in CD33 and CD163 populations, particularly in kidney cancer and sarcoma. Moreover, we found that tumor infiltrating CD8 T-cells often expressed VISTA, notably in sarcoma, kidney cancer, and hepatocellular carcinoma.
Conclusions
Finally, we propose indications of interest that may support patient selection strategy for the development of anti-VISTA treatments.
Legal entity responsible for the study
Pierre Fabre Laboratories.
Funding
Pierre Fabre Laboratories.
Disclosure
P. Launay, A. Pillon, R. Bonnet, D. Vinet, A. Alloy, L. Lacastaigneratte, C. Welsch, C. Larzabal, G. Zorza, G. Gueguen Dorbes, O. Geneste, F. Hofmann, M-O. Roy: Financial Interests, Personal, Full or part-time Employment: Pierre Fabre.
Resources from the same session
200P - A novel multi-organ on chip model for metastatic tumor biology understanding
Presenter: Elisabetta Palama
Session: Poster Display
201P - Role of aerobic exercise training on the mitochondrial metabolism and effector function of CD8+ tumor-infiltrating lymphocytes
Presenter: Janaina Vieira
Session: Poster Display
202P - Discovery of immunological cellular neighborhoods from protein markers in spatial tumor data
Presenter: Marcin Mozejko
Session: Poster Display
203P - Identification of High Confidence Candidate Markers for Macrophage Infiltrating Tumor Microenvironment through Single Cell Genomic Atlases
Presenter: Constance Ciaudo Beyer
Session: Poster Display
204P - Effect of STAT6 Inhibition as a Novel Strategy for Promoting the Induction of Potent and Stable Regulatory T Cells for Use in Colitis Therapy
Presenter: SONIA LEON-CABRERA
Session: Poster Display